Weekly View

ICER Weekly View 06-23-17

From the desk of Mitchell Stein   Good morning. Did everyone have fun staying up late reading the Senate health care bill and the resulting avalanche of analysis? No, just me? Anyway, despite the focus on the latest repeal and replace developments, as always there is still lots to talk about in the pharma […]

Read More

ICER Weekly View 06-16-17

From the desk of Mitchell Stein   Good morning. Lots of ICER activity this week, so much in fact that there’s no “In-depth” feature so you have time to read about everything going on. Specifically, this week we’ll look at: ICER in the news – Wired magazine in-depth feature, Evidence Update on PCSK9 inhibitors along […]

Read More

ICER Weekly View 06-09-17

From the desk of Mitchell Stein   Good morning. Lordy, there was a lot of news coming out of ASCO. So much, in fact, that the results have taken over two sections this week: Company/Drug Specific News and Weekly View In-depth both focus on the conference. Here’s the full run-down: ICER in the news – […]

Read More

ICER Weekly View 06-02-17

From the desk of Mitchell Stein   Good morning. The non-drug related news continues to heat-up in DC, and that trend will only increase with yesterday’s announcement. Meanwhile, lots to talk about in the pharma world, not least of which is the start of the ASCO conference in Chicago today. This week we’ll look at: […]

Read More

ICER Weekly View 05-26-17

From the desk of Mitchell Stein   Good morning. Before thoughts turn to the long weekend (despite the very un-summery weather here in the Northeast) we have some news to discuss. This week we’ll look at: ICER in the news – Pearson on value thresholds, Dreitlein on gene therapies, sarilumab approval (2 stories), and Pearson […]

Read More

ICER Weekly View 05-19-17

From the desk of Mitchell Stein   Good morning. It would be easy to get distracted by the Administration’s ongoing issues, yet the world continues to revolve on its axis, the sun continues to shine (yesterday a bit too warmly if you ask me), and the world of prescription drugs continues to function. So I […]

Read More

ICER Weekly View 05-12-17

From the desk of Mitchell Stein   Good morning. I’ve got nothing today – any jokes I make about the goings on in DC would pale in comparison to the reality – so let’s just talk about drugs. This week we’ll look at: ICER in the news – Orphan Drug paper released, draft evidence […]

Read More

ICER Weekly View 05-05-17

From the desk of Mitchell Stein   Good morning. It finally happened, the House passed the AHCA. As you might imagine, that occupied much of this week’s healthcare bandwidth; yet the world continued to revolve on its axis and news continued to be generated by the pharmacy industry. So no time off for us, instead […]

Read More

ICER Weekly View 04-28-17

From the desk of Mitchell Stein   Good morning. It’s Friday, so it’s time once again to report there will be no AHCA vote today. There’s also still no budget, but no worries, Congress still has another day before a shut-down, so there’s still plenty of time for an agreement. While all that is going […]

Read More

ICER Weekly View 04-21-17

From the desk of Mitchell Stein   Good morning. Rumors of a new healthcare deal in Congress have been greatly exaggerated; instead, expect the focus next week to be on the minor issue of funding the government. While all that is going on in DC, this week we’ll look at: ICER in the news – […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP